semaglutide efficacy and safety of once-weekly 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial Semaglutide: Double-edged Sword with Risks

But the key reality check is that Novos own 2026 guide is still for adjusted sales growth of negative 5% to negative 13% at CER, reflecting pricing pressure, competition, and U.S

How tirzepatide differs from other GLP-1 medications Worth noting: tirzepatide has a greater impact on oral contraceptive absorption than other GLP-1 receptor agonists like semaglutide

Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus

As the medication leaves your body, your appetite and cravings come back

Only about one in five large employers currently offer GLP-1s for weight loss, according to a new survey from the Kaiser Family Foundation

A request has been filed in New Jersey state courts to consolidate lawsuits related to NAION and GLP-1 drugs